<DOC>
	<DOC>NCT01316315</DOC>
	<brief_summary>The purpose of this study is to determine whether a single IV dose of N6022 will have a significant bronchoprotective effect, compared with placebo, during methacholine challenge.</brief_summary>
	<brief_title>Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma</brief_title>
	<detailed_description>The number of patients with adverse events measured in both the treated and placebo groups from start of dosing until Day 28 post dose.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Body mass index (BMI) between 18.5 and 35 kg/m2, inclusive, at screening. Patient has a ≤ 5 pack years smoking history and nonsmoking for ≥ one year. Documented history of mild bronchial asthma, first diagnosed at least 6 months and currently being treated only with intermittent shortacting betaagonist therapy by inhalation. Prebronchodilator FEV1 ≥ 75% of predicted at screening. Sensitivity to methacholine with a provocation concentration of methacholine resulting in a 20% fall in FEV1 (PC20 methacholine) of ≤ 8 mg/ml at screening. Demonstrated stable lung function during screening with ≤10% variability between two assessments of FEV1 taken at least 7 days apart at approximately the same time of day. Hypertension at screening is defined as systolic blood pressure (BP) &gt;150 mmHg or diastolic BP &gt; 90mmHg. Respiratory tract infection and/or exacerbation of asthma within prior 4 weeks History of lifethreatening asthma Administration of steroids within 4 weeks of the screening visit. History of being unable to tolerate or complete MCh testing. Blood donation (500 mL) within 3 months of starting the clinical study. Tested positive for hepatitis C antibody or hepatitis B surface antigen. Tested positive for human immunodeficiency virus (HIV) antibodies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>